Talk:PD-1 and PD-L1 inhibitors

Should give more weight to PD-1 inhibitors ?
More of them have been approved eg by the FDA, yet this article seems to ignore their existence. - Rod57 (talk) 21:31, 12 June 2016 (UTC)

May be able to use on mCRC (eg with MEK-inhibitors)
[https://www.sciencedaily.com/releases/2016/06/160629105936.htm Anti-PD-L1 immunotherapy responsive in microsatellite-stable mCRC comb with MEK inhibition. une 2016] says it can be helpful to use them with MEK-inhibitors for mCRC types that have previously been hard to treat with immunotherapies. - Rod57 (talk) 21:22, 2 July 2016 (UTC)

Adverse effects should mention hyperprogressive disease
Adverse effects section should mention hyperprogressive disease' per Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy - Rod57 (talk) 17:00, 21 September 2018 (UTC)